regulus therapeutics inc
(RGLS:NASDAQ GM)
regulus therapeutics inc (RGLS) Snapshot
|
Open
$7.11
|
Previous Close
$7.00
|
|
|
Day High
$7.11
|
Day Low
$6.98
|
|
|
52 Week High
03/21/13 - $7.89
|
52 Week Low
10/3/12 - $4.00
|
|
|
Market Cap
252.1M
|
Average Volume 10 Days
42.7K
|
|
|
EPS TTM
--
|
Shares Outstanding
36.0M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
regulus therapeutics inc (RGLS) Related Businessweek News
regulus therapeutics inc (RGLS) Details
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of microRNA therapeutics to treat a range of diseases primarily in the United States. The company is developing various oligonucleotides, including miR-21 for hepatocellular carcinoma and for kidney fibrosis, miR-122 for hepatitis C virus infection, miR-33 for atherosclerosis, and miR-10b for glioblastoma multiforme treatment. It has strategic alliance with GlaxoSmithKline plc; and collaboration and license agreement with Sanofi, AstraZeneca, Alnylam and Isis, and Biogen Idec MA Inc. The company was founded in 2007 and is headquartered in San Diego, California.
regulus therapeutics inc (RGLS) Top Compensated Officers
regulus therapeutics inc (RGLS) Key Developments
Regulus Therapeutics Inc. reported unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from operations of $5,550,000 against $2,180,000 for the same period last year. Loss before income taxes was $7,239,000 against $2,246,000 for the same period last year. Net loss was $7,229,000 or $0.20 per basic and diluted share against $2,247,000 or $13.06 per basic and diluted share for the same period last year. The company recognized revenue of $3.2 million compared to $3.3 million for the same period last year. Revenue during these periods consisted primarily of amortization of up-front payments received from strategic alliances and collaborations, which is recognized over the estimated period of performance.
Regulus Therapeutics Inc., Q1 2013 Earnings Call, May 14, 2013
Regulus Therapeutics Inc. announced that they will report Q1, 2013 results at 5:00 PM, Eastern Standard Time on May 14, 2013
| Recently Viewed | |||
| RGLS:US | $7.00 USD | 0.00 |  |
| Company | Last | Change |
| Arrowhead Research Corp | $2.18 USD | +0.05 |
| Enzon Pharmaceuticals Inc | $3.13 USD | 0.00 |
| Marina Biotech Inc | $0.27 USD | +0.02 |
| Silence Therapeutics PLC | 205.00 GBp | -3.00 |
| Tekmira Pharmaceuticals Corp | C$4.85 CAD | 0.00 |
| View Industry Companies | ||
Industry Analysis
RGLS
Industry Average
| Valuation | RGLS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 20.2x |
|
| Price/Book | 4.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 12.2x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: May 20
Sponsored Financial Commentaries
Sponsored Links
To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
